Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance

DSpace/Manakin Repository

Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance

Citable link to this page

 

 
Title: Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Author: Kats, Lev M.; Reschke, Markus; Taulli, Riccardo; Pozdnyakova, Olga O.; Burgess, Kerri; Bhargava, Parul; Straley, Kimberly; Karnik, Rahul; Meissner, Alexander; Small, Donald; Su, Shinsan M.; Yen, Katharine; Zhang, Jiangwen; Pandolfi, Pier Paolo

Note: Order does not necessarily reflect citation order of authors.

Citation: Kats, Lev M., Markus Reschke, Riccardo Taulli, Olga Pozdnyakova, Kerri Burgess, Parul Bhargava, Kimberly Straley, et al. 2014. “Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance.” Cell Stem Cell 14 (3) (March): 329–341. doi:10.1016/j.stem.2013.12.016.
Access Status: Full text of the requested work is not available in DASH at this time (“dark deposit”). For more information on dark deposits, see our FAQ.
Full Text & Related Files:
Abstract: Mutations in the metabolic enzymes isocitrate dehydrogenase-1 (IDH1) and IDH2 that produce the oncometabolite D-2-hydroxyglutarate (2-HG) occur frequently in human acute myeloid leukemia (AML). 2-HG modulates numerous biological pathways implicated in malignant transformation, but the contribution of mutant IDH proteins to maintenance and progression of AML in vivo is currently unknown. To answer this crucial question we have generated transgenic mice that express IDH2R140Q in an on/off- and tissue-specific manner using a tetracycline-inducible system. We found that IDH2R140Q can cooperate with overexpression of HoxA9 and Meis1a and with mutations in FMS-like tyrosine kinase 3 (FLT3) to drive acute leukemia in vivo. Critically, we show that genetic deinduction of mutant IDH2 in leukemic cells in vivo has profound effects on their growth and/or maintenance. Our data demonstrate the proto-oncogenic role of mutant IDH2 and support its relevance as a therapeutic target for the treatment of human AML.
Published Version: doi:10.1016/j.stem.2013.12.016
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33471094
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters